In conclusion, as mentioned earlier, GDF-15 could have an adverse effect on sarcopenia and decrease skeletal muscle mass by activating FOXO1 and SMAD3, however, its protecting role against insulin resistance could reverse the process of sarcopenia. Here, FOXO1 is linked to sarcopenia.